TRIL Antikörper (C-Term)

Produktnummer ABIN6252855

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch TRIL in WB. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für TRIL Antikörper (C-Term) (ABIN6252855)

Target: TRIL (TLR4 Interactor with Leucine-Rich Repeats (TRIL))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser TRIL Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Produktdetails anti-TRIL Antikörper

Bindungsspezifität: C-Term

Aufreinigung: Protein A affinity chromatography

Immunogen: A recombinant protein fragment from the C-terminal region of human TRIL was used as the immunogen for this antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western blot: 2-5 μg/mL

Provided assay concentrations are suggestions only, antibody titration may be required for optimal results.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.5 mg/mL

Buffer: PBS with 0.1 mg/mL BSA and 0.05 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot and Store at -20C. Avoid freez-thaw cycles.

Details zu TRIL

Target: TRIL (TLR4 Interactor with Leucine-Rich Repeats (TRIL))

Andere Bezeichnung: TRIL

Hintergrund: TRIL or TLR4 interactor with leucine rich repeats, is a protein encoded by the human KIAA0644 gene. TRIL protein sequence is highly conserved across species. It is expressed in a number of tissues with highest expression in brain, ovary, small intestine and spleen. TRIL is an accessory molecule that interacts with TLR3 and endosomal TLR4, enhancing their interaction with their ligands, poly(I:C) and LPS, and increasing the production of type I interferons in the innate immune response.

Gen-ID: 9865

UniProt: Q7L0X0

Pathways: Activation of Innate immune Response, Production of Molecular Mediator of Immune Response